STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Co - TAK STOCK NEWS

Welcome to our dedicated news page for Takeda Pharmaceutical Co (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Takeda Pharmaceutical Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Takeda Pharmaceutical Co's position in the market.

News
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) receives positive CHMP opinion for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for CIDP patients, offering a potential once-monthly subcutaneous treatment option. The Phase 3 ADVANCE-CIDP 1 study met its primary endpoint, demonstrating a statistically significant reduction in relapse rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
Rhea-AI Summary
Takeda (4502/TAK) and The New York Academy of Sciences award the 2024 Innovators in Science Award to Dr. Robert D. Schreiber and Dr. Elham Azizi for their significant contributions to cancer immunology. Each winner receives an unrestricted prize of USD 200,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
-
News
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
Rhea-AI Summary
Takeda (4502/TAK) to Present 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology at ASH Annual Meeting. New Data from Phase 3 Trials Supporting FDA Approval of ADZYNMA and Insights into Treatment of Ph+ Acute Lymphoblastic Leukemia and Hodgkin Lymphoma to be Featured.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
News
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has announced that the FDA approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). This ultra-rare blood clotting disorder is associated with life-threatening acute events and debilitating chronic symptoms. ADZYNMA is the first FDA-approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
News
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has received FDA approval for FRUZAQLA™, a targeted therapy for metastatic colorectal cancer. FRUZAQLA demonstrated significant improvements in overall survival and progression free survival in two Phase 3 clinical trials. This approval marks the first novel chemotherapy-free treatment option for mCRC patients in the U.S. in over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
fda approval
-
News
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
Rhea-AI Summary
Takeda announces positive results from a Phase 2b trial evaluating TAK-279 for the treatment of psoriatic arthritis, with the drug meeting its primary endpoint and demonstrating improvements in key secondary endpoints. The company plans to initiate Phase 3 studies in plaque psoriasis and psoriatic arthritis, while exploring TAK-279 in other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
clinical trial
News
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
Rhea-AI Summary
Takeda announces financial results for the first half of fiscal year 2023, reporting revenue growth of +6.4% at AER and +1.4% at CER. Core operating profit decreased by -9.5% at CER. Full-year revenue and core EPS forecasts have been raised, while full-year profit forecasts have been lowered. No change to free cash flow outlook or management guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
none
-
News
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Rhea-AI Summary
Takeda's ADCETRIS receives European Commission approval for the treatment of previously untreated CD30+ Stage III Hodgkin lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
News
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
Rhea-AI Summary
Takeda settles tax assessment with Irish Revenue for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
News
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
Rhea-AI Summary
Takeda's Phase 3 study for Alofisel in treating Crohn's Perianal Fistulas does not meet primary endpoint
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
clinical trial
Stock TAK logo
Takeda Pharmaceutical Co

NYSE:TAK

TAK Rankings

#298 Ranked by Market Cap
#1877 Ranked by Stock Gains
#668 Ranked by Dividends

TAK Stock Data

42.46B
1.55B
0%
2.67%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Japan
Chuo Ku

About TAK

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.